Latest news with #Astellas
Korea Herald
6 days ago
- Business
- Korea Herald
Astellas Chooses Veeva Vault CRM as Global Standard
Vault CRM will support Astellas' commercial agility and execution SINGAPORE, June 5, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients." "Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions," said Matt Farrell, president, commercial strategy at Veeva. "With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission." Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution. About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at
Associated Press
6 days ago
- Business
- Associated Press
Astellas Chooses Veeva Vault CRM as Global Standard
Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. 'At Astellas, we discover and deliver transformative therapies for patients around the world,' said Nick Eshkenazi, chief digital and transformation officer at Astellas. 'Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients.' 'Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions,' said Matt Farrell, president, commercial strategy at Veeva. 'With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission.' Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution. About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at Contact: Alison Borris Veeva Systems 925-226-8821 [email protected] View original content to download multimedia: SOURCE Veeva Systems
Yahoo
6 days ago
- Business
- Yahoo
Astellas Chooses Veeva Vault CRM as Global Standard
Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients." "Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions," said Matt Farrell, president, commercial strategy at Veeva. "With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission." Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution. About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at Contact: Alison BorrisVeeva View original content to download multimedia: SOURCE Veeva Systems
Yahoo
30-05-2025
- Business
- Yahoo
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study of patients with solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer - - Evopoint to receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved - TOKYO and SUZHOU, China, May 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2. The agreement grants Astellas a worldwide (excluding China's mainland, Hong Kong, Macao and Taiwan region) exclusive license to develop and commercialize XNW27011. XNW27011 is currently being evaluated in a Phase 1/2 study in China in patients with CLDN18.2-expressing solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer. It uses a proprietary topoisomerase I inhibitor payload and linker technology, an approach that has demonstrated clinical success in other approved cancer therapies. Astellas has significant expertise in developing therapies that target CLDN18.2, including VYLOYTM, the first CLDN18.2-targeted therapy approved in the world. XNW27011 has the potential to address currently unmet patient need and will expand Astellas' oncology pipeline which currently contains CLDN-targeting therapies utilizing different approaches, as well as ADC's directed to other targets. Under the terms of the agreement, Evopoint will receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved. Adam Pearson, Chief Strategy Officer, Astellas"Astellas is dedicated to advancing innovative therapies for some of the most challenging-to-treat cancers, such as gastric and pancreatic cancer. XNW27011 is a promising new asset that complements Astellas' pipeline and enhances our leading position in precision oncology. We look forward to harnessing our expertise in targeting CLDN18.2 and specialized knowledge in GI cancers to advance XNW27011 and deliver meaningful outcomes to patients." Arthur Qiang, Chairman, Evopoint"XNW27011 is a novel investigational antibody-drug conjugate that has shown great promise in the clinic. Astellas has a proven history of developing and commercializing a strong franchise of innovative cancer therapies. We are pleased to enter into this new license agreement to further our collective goals of bringing new treatment options for patients in need worldwide." About AstellasAstellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at About Evopoint BiosciencesEvopoint Biosciences is an innovative biopharmaceutical company with exceptional capabilities in R&D and commercialization. Since its inception, Evopoint has been committed to improving human health by discovering and developing cutting-edge pharmaceutical solutions that address significant unmet medical needs worldwide. Leveraging diverse discovery platforms in targeted therapy, ADC, and targeted protein degradation (TPD), the company has built a robust pipeline focused on oncology, infectious diseases and metabolic diseases. Learn more at Astellas Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. View original content to download multimedia: SOURCE Astellas Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Times
28-05-2025
- Business
- Irish Times
Japanese pharmaceutical firm Astellas claims top honour at Manufacturing Excellence Awards 2025
A Japanese pharmaceutical manufacturer with operations in Co Kerry has been named the overall winner at the Manufacturing Excellence Awards 2025, held at the Crowne Plaza Hotel in Santry in Dublin. Astellas Ireland's Killorglin plant, which manufactures treatments including the immunosuppressant Prograf, was selected by a distinguished judging panel for exceptional performance across innovation, quality, sustainability and operational efficiency. The judging panel's citation stated that Astellas had 'set a benchmark in Irish manufacturing, demonstrating leadership, adaptability and a commitment to continuous improvement'. James O'Neill, lead pharma manufacturing operations at Astellas, commented: 'It's the first time entering from our operations and manufacturing side of things. The award win helps promote your site, what you're doing and what you're best in class at.' READ MORE The Kerry plant, established in 1990, employs 250 permanent staff and has made notable environmental advances, with its wind turbine and wood chip boiler reducing carbon dioxide emissions by more than 3,000 tonnes annually. The facility also won the award in the waste management category. Now in its second year, the Manufacturing Excellence Awards attracted 72 entries from 42 companies across Ireland. The ceremony was hosted by Colm O'Regan and attended by 134 industry professionals, with 17 trophies presented across various categories recognising excellence in Irish manufacturing. The Irish Manufacturing Council serves as the strategic partner for the awards programme, helping to promote collaboration between industries and the Council. Guangbo Hao, IMC secretary, highlighted the importance of the programme. 'The awards are a great opportunity to assess and recognise the excellence of the industries and a significant promotion for the collaboration between the industries and IMC,' he said. Among the award winners, Redmond McDonnell, chief executive of DesignPro Automation, expressed delight at winning in the manufacturer category, noting 'whenever you win amongst your peers, it's always a very good thing' and highlighting the value of recognition among customers and suppliers. John Byrne, chief executive of Hygeia, called it 'a fantastic achievement' for their 85-year-old company to win in the manufacturer category, noting that the recognition is 'an acknowledgment for both company and staff for what's been achieved through the year'. Judging coordinator Matt Cotterell noted that the Manufacturing Excellence Awards showcase the diversity of activities and capabilities within the Irish manufacturing sector. 'The awards feature companies that make a very valuable contribution to the Irish economy, providing a great range of employment opportunities whilst enriching the communities where they are based,' he said. Dr Cotterell explained that manufacturing is a team activity requiring multiple disciplinary activities with a focus on continuous improvement and customer satisfaction. 'It is technology-enabled but people are key, and the awards ceremony celebrates the valuable contribution of people in enabling companies to succeed and is a great networking event.' Winners of the Manufacturing Excellence Awards 2025 He added that sustainability and digital transformation are themes that featured strongly in all the award categories. 'Real-time monitoring of processes and systems performance is being implemented across the supply chain by manufacturers, allowing them to make data-informed decisions and improvements.' Heber McMahon, director of sales at Cygnum Timber Frame, said it was 'a pleasure' to be recognised alongside notable companies. Paul Murray, supply chain manager at Aryzta Ireland, noted that the company's award entry was well received. 'There are many other companies that we worked with who would have the standards that we have and we'll be speaking to them in due course,' he added. Boston Scientific Galway was the award winner in the manufacturing team category. 'We were delighted to take part in the awards night, and to be recognised amongst the high calibre companies was truly inspiring,' said Jonathan Carr, principal manufacturing engineer. 'The whole process and the evening event were extremely well run.' Cormac McAteer, senior engineering manager at Seagate Technology, commented that the awards 'demonstrate how capable you are as a company' when developing partnerships. Jade Power, ESG & contracts manager at Glenpatrick Spring Water, described being 'absolutely thrilled' that the firm was shortlisted, adding that the trophy win was 'the cream on top of the cake'. Adam Kane, community lead at events organiser Business River, stated: 'Events like this are made possible through the support of our partners. We are thankful to our strategic partner, Irish Manufacturing Council. I also want to recognise our communications partner, The Irish Times, as well as our supporter, Amárach Research. Their investment in the awards underlines their commitment and support of this key business area.' Dr Matt Cotterell (judging coordinator) – head of school of mechanical, electrical and process engineering, Munster Technological University Dr John Cosgrove – director of Smart Manufacturing, Technological University of the Shannon Barry Cox – standards development manager, National Standards Authority Of Ireland Jill Ellis – senior lecturer in food manufacturing, The National Centre for Food Manufacturing, University of Lincoln Guangbo Hao – professor in mechanical engineering, University College Cork (UCC) Rocco Lupoi – associate professor, School of Engineering, Trinity College Dublin Margaret Morgan – professor, Ulster University Joe O'Callaghan – programme director, UCC Morteza Tabatabaeipour – assistant professor, Ulster University Overall manufacturing excellence award Winner: Astellas Ireland (Kerry plant) Dr Matt Cotterell, awards judging coordinator and committee member at Irish Manufacturing Council, presents the overall manufacturing excellence award to the Astellas Ireland (Kerry Plant) team Manufacturing team of the year Winner: Boston Scientific Galway – PSPI Team Dr Matt Cotterell, awards judging coordinator and committee member at Irish Manufacturing Council, presents the manufacturing team of the year award to Jonathan Carr, Boston Scientific Galway Manufacturer of the year – large business Winner: Astellas Ireland (Kerry plant) Adam Kane, community lead at Business River, presents the manufacturer of the year - large business award to James O'Neill, Astellas Ireland (Kerry Plant) Manufacturer of the year – medium business Winner: DesignPro Automation Adam Kane, community lead at Business River, presents the manufacturer of the year - medium business award to Redmond McDonnell and Conor Doyle, DesignPro Automation Manufacturer of the year – small business Winner: Hygeia Adam Kane, community lead at Business River, presents the manufacturer of the year - small business award to John Byrne, Hygeia Manufacturer of the year – food & beverages Winner: Glenpatrick Spring Water Adam Kane, community lead at Business River, presents the manufacturer of the year - food & beverages award to Jade Power, Glenpatrick Spring Water Manufacturer of the year – life sciences Winner: Lawrence Engineering Adam Kane, community lead at Business River, presents the manufacturer of the year - life sciences award to Anthony McKeon, Lawrence Engineering Manufacturer of the year – wood products Winner: Cygnum Timber Frame Dr Emmett Kerr, committee member at Irish Manufacturing Council, presents the manufacturer of the year - wood products award to Heber McMahon, Cygnum Timber Frame Operational excellence award Winner: Viatris Little Island Dr Emmett Kerr, committee member at Irish Manufacturing Council, presents the operational excellence award to Donogh McCarthy, Viatris Little Island HR achievement award Winner: Irish Distillers Dr Emmett Kerr, committee member at Irish Manufacturing Council, presents the HR achievement award to Emily Moran, Irish Distillers Digital transformation award (sponsored by Irish Manufacturing Council) Winner: Boston Scientific Clonmel Dr Emmett Kerr, committee member at Irish Manufacturing Council, presents the digital transformation award to Sean Ward, Boston Scientific Clonmel Supply chain achievement award Winner: Aryzta Ireland Prof Ger Kelly, committee member at Irish Manufacturing Council, presents the supply chain achievement award to Paul Murray, ARYZTA Ireland Excellence in health & safety Winner: Aerogen Prof Ger Kelly, committee member at Irish Manufacturing Council, presents the excellence in health & safety award to Declan Lynch, Aerogen Waste management award Winner: Astellas Ireland (Kerry plant) Professor Ger Kelly, committee member at Irish Manufacturing Council, presents the waste management award to Eoghan Barry, Astellas Ireland (Kerry Plant) Energy achievement award Winner: C&D Foods Dr Guangbo Hao, committee member at Irish Manufacturing Council, presents the energy achievement award to Adam Kane, Business River on behalf of C&D Foods Innovation of the year Winner: Heron Joinery – Custom Roller/Turntable Dr Guangbo Hao, committee member at Irish Manufacturing Council, presents the innovation of the year award to Michael Bell, Heron Joinery Best use of technology Winner: Seagate Technology – AI-Enabled Generic Image Focus Quality System Dr Guangbo Hao, committee member at Irish Manufacturing Council, presents the best use of technology award to Cormac McAteer, Seagate Technology
